RESPONSE EVALUATION OF TAMOXIFEN VS AROMATASE INHIBITORS
Saba Mazhar, Mariam Nawaz, Muhammad Tahir Aziz, Sidrah Andleeb
Department of Pharmaceutical Services, SKMCH&RC, Lahore, Pakistan
Keywords: Tamoxifen, aromatase inhibitor, breast cancer
Objective:The study was conducted to evaluate the accuracy of use of aromatase inhibitors (AI) and tamoxifen treatment in pre-menopausal and post-menopausal breast cancer patients.
Method: The prescription data of 143 patients was reviewed for evaluation of letrozole, anastrazole and tamoxifen utilization between years 2006-2013 at SKMCH&RC. Use was analyzed against pre-menopausal and post-menopausal status of the patients using hospital information software (HIS) for data collection. NCCN Breast Cancer Guidelines were used as reference.
Results:Tamoxifen upfront use in pre-menopausal women with breast cancer was 93.3%, while that of Aromatase inhibitor was 6.7%. Tamoxifen was used as second line therapy in pre-menopausal women in 6.7% while aromatase inhibitor was used as second line therapy in pre-menopausal women in 93.3%. Tamoxifen upfront in post-menopausal was 18.6%, aromatase inhibitor upfront in post-menopausal was 81.4%.
Conclusion:Tamoxifen is used as first line therapy in majority of pre-menopausal breast cancer patients while aromatase inhibitors are used as second line. In case of post-menopausal breast cancer patients aromatase inhibitors are used as first line in majority of patients while tamoxifen is used as second line.
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits